Onco IX (PHC-102) is a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors. The product consists of (i) an acetazolamide ligand derivative specific to CAIX, (ii) a non-cleavable spacer and (iii) a peptide chelator.
CAIX is a validated target, which is not only expressed in the vast majority of Renal Cell Carcinoma (RCC), but also in
other hypoxic tumors (e.g., a proportion of Colorectal Carcinoma and High-Grade Glioma).
In preclinical studies, PHC-102 has demonstrated a high tumor uptake and favourable tumor-to-organ ratios.
The in vivo targeting properties of Onco IX have been validated both in preclinical models and in human patients with advanced RCC tumors.
Millul et al. (2021) Mol Cancer Ther, 20, 512-22
Kulterer et al. (2021) J Nucl Med, 62, 360-365
Cazzamalli et al. (2018) Clin Cancer Res, 24, 3656-67
Cazzamalli et al. (2018) J Am Chem Soc, 140, 1617-21
Cazzamalli et al. (2017) J Control Release, 246, 39-45
Cazzamalli et al., (2016) Mol Cancer Ther, 15, 2926-35
Krall et al. (2016) J. Nucl Med, 57, 943-9
Wichert et al. (2015) Nat Chem, 7, 241-9
Krall et al. (2014) Chem Sci, 5, 3640-4
Krall et al. (2014) Angew Chem Int Ed, 53, 4231-35